Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Hikaru Okada"'
Autor:
Alix Arnaud MS, Samantha Schilsky PhD, MPH, Jackie Lucia BS, Marta Maia MS, Fernando Laredo MS, Ana Paula Marques MD, Hikaru Okada MD, PhD, Andrew W. Roberts PharmD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics, treatment patter
Externí odkaz:
https://doaj.org/article/57ed4bbdb186466689910ea32b319189
Autor:
Sriya GUNAWARDENA, MD, Angela HU, MD, Laurel A. MENAPACE, MD, Hikaru OKADA, MD, PhD, Beverly ACCOMANDO, MS, Julie LIN, MD
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S38-S39 (2023)
Objective: Caplacizumab (CPLZ) is indicated, in combination with therapeutic plasma exchange (TPE) and immunosuppressive therapy (IST), for the treatment of immune-mediated TTP (iTTP). TPE is a mainstay of iTTP treatment but is burdensome and associa
Externí odkaz:
https://doaj.org/article/2a7999efa2b34245b549391242067d1e
Autor:
Naoki Kodama, Hikaru Okada, Masakazu Hachisu, Miki Ando, Naoto Ito, Kazuki Nagata, Mayuka Katagiri, Yayoi Yasuda, Ikumi Hiroki, Takuya Yashiro, Gaku Ichihara, Masayuki Yamamoto, Chiharu Nishiyama
Publikováno v:
Frontiers in Nutrition, Vol 10 (2023)
Dendritic cells (DCs), which are typical antigen-presenting cells, localize to various sites in the body, particularly the front line of infection as sentinels, and are involved in innate and adaptive immune responses. Although the functions of DCs,
Externí odkaz:
https://doaj.org/article/ef4cb22f53c24cdaba6c6dc6a6180120
Autor:
Hiroshi Tanei, Hikaru Okada, Masahiro Susa, Megumi Akoshima, Hiromichi Watanabe, Miyuki Hayashi, Yuanru Yang, Rie Endo
Publikováno v:
ISIJ International. 61:26-32
Autor:
Megumi Akoshima, Mu Li, Masahiro Susa, Miyuki Hayashi, Hiroki Hayashi, Hiroshi Tanei, Hikaru Okada, Rie Endo
Publikováno v:
ISIJ International. 60(No. 12):2773-2779
Publikováno v:
Blood. 140:2770-2771
Autor:
Naoki Kodama, Hikaru Okada, Masakazu Hachisu, Miki Ando, Naoto Ito, Kazuki Nagata, Yayoi Yasuda, Ikumi Hiroki, Takuya Yashiro, Gaku Ichihara, Masayuki Yamamoto, Chiharu Nishiyama
Dendritic cells (DCs), which are typical antigen-presenting cells, localize to various sites in the body, particularly the front line of infection as sentinels, and are involved in innate and adaptive immune responses. Although the functions of DCs,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2bf79f40f4ef0216ef7f1c2fd73be4a
https://doi.org/10.1101/2022.02.08.479651
https://doi.org/10.1101/2022.02.08.479651
Autor:
Shigeki Saito, Tatsuya Kawaguchi, Junichi Tsukada, Toshihiro Miyamoto, Hisashi Tsurumi, Masafumi Taniwaki, Kohmei Kubo, Hikaru Okada, Makoto Aoki, Kazuhito Yamamoto, Tomoko Hata, Shinya Kimura, Midori Kondo, Itaru Matsumura, Masamitsu Yanada, Koichi Miyamura, Kazuma Ohyashiki, Kuniaki Meguro, Hideo Hyodo, Masayuki Hino, Masahide Yamamoto, Mitsune Tanimoto, Seiji Tadokoro
Publikováno v:
Leukemia Research. 51:11-18
Optimal management of patients with chronic myeloid leukemia in chronic phase with suboptimal molecular response (MR) to frontline imatinib is undefined. We report final results from SENSOR, which evaluated efficacy/safety of nilotinib in this settin
Autor:
Toshio Yonezu, Taro Amagasaki, Norio Komatsu, Hikaru Okada, Keita Kirito, Koichi Akashi, Kazuya Shimoda, Kazuma Ohyashiki, Takayuki Ishikawa, Naoto Takahashi, Kohshi Ohishi
Publikováno v:
International Journal of Hematology. 105:309-317
Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly, symptoms, and overall survival in controlled clinical trials in patients with myelofibrosis. The single-arm study reported here was initiated to c